Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease

• Published in: Brain, behavior, and immunity Vol. 70; pp. 194 - 202
• Main Authors: Qian, Yiwei, Yang, Xiaodong, Xu, Shaoqing, Wu, Chunyan, Song, Yanyan, Qin, Nan, Chen, Sheng-Di, Xiao, Qin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.05.2018
• Subjects: 16S rRNA gene; Gut microbiota; Neurodegenerative disorder; Neurodegenerative disorder; Gut microbiota; 16S rRNA gene
• ISSN: 0889-1591; 1090-2139
• DOI: 10.1016/j.bbi.2018.02.016

•Alteration of the fecal microbiota was confirmed in Chinese patients with PD.•A well-controlled population was benefit for the identification of microbiota associated with the disease.•More genera in the feces were associated with non-motor symptoms, especially with cognitive impairment. Emerging evidences suggest that gut microbiota dysbiosis plays a role in Parkinson’s disease (PD). However, the alterations in fecal microbiome in Chinese PD patients remains unknown. This case-control study was conducted to explore fecal microbiota compositions in Chinese PD patients. Microbiota communities in the feces of 45 patients and their healthy spouses were investigated using high-throughput Illumina Miseq sequencing targeting the V3-V4 region of 16S ribosomal RNA (rRNA) gene. The relationships between fecal microbiota and PD clinical characteristics were analyzed. The structure and richness of the fecal microbiota differed between PD patients and healthy controls. Genera Clostridium IV, Aquabacterium, Holdemania, Sphingomonas, Clostridium XVIII, Butyricicoccus and Anaerotruncus were enriched in the feces of PD patients after adjusting for age, gender, body mass index (BMI), and constipation. Furthermore, genera Escherichia/Shigella were negatively associated with disease duration. Genera Dorea and Phascolarctobacterium were negatively associated with levodopa equivalent doses (LED). Among the non-motor symptoms (NMSs), genera Butyricicoccus and Clostridium XlVb were associated with cognitive impairment. Overall, we confirmed that gut microbiota dysbiosis occurs in Chinese patients with PD. A well-controlled population involved was beneficial for the identification of microbiota associated with diseases. Additionally, the fecal microbiota was closely related to PD clinical characteristics. Elucidating these differences in the fecal microbiome will provide a foundation to improve our understanding the pathogenesis of PD and to support the potentially therapeutic options modifying the gut microbiota.